走進(jìn)諾和諾德 更多 >>
諾和諾德是一家致力于人類健康、以先進(jìn)的生物技術(shù)造?；颊?、醫(yī)生和社會(huì)的世界領(lǐng)先生物制藥公司。
諾和諾德公司的歷史最早可追溯至1923年，80多年來(lái)一直是世界糖尿病研究和藥物開發(fā)領(lǐng)域的主導(dǎo)。諾和諾德總部位于丹麥?zhǔn)锥几绫竟?，現(xiàn)在全球79個(gè)國(guó)家設(shè)有分支機(jī)構(gòu)，6個(gè)國(guó)家設(shè)有生產(chǎn)廠，截至08年底，員工超過(guò) 27，000名，銷售遍及180個(gè)國(guó)家。
諾和諾德憑借自身的研發(fā)實(shí)力成為世界糖尿病治療領(lǐng)域先導(dǎo)，在行業(yè)內(nèi)擁有最為廣泛的糖尿病治療產(chǎn)品，其中包括最先進(jìn)的胰島素給藥系統(tǒng)產(chǎn)品。
?
從RCT到臨床實(shí)踐：觀察性研究的相關(guān)性
發(fā)布日期：2009-12-09 17:29 文章來(lái)源：丁香園
分享到： 收藏夾 新浪微博 騰訊微博 開心網(wǎng) 豆瓣社區(qū) 人人網(wǎng)
關(guān)鍵詞： 諾和銳
諾和諾德
novonordisk
Robert
Ligthelm
RCT
臨床
胰島素
糖尿病
點(diǎn)擊次數(shù)：
From RCT to clinical practice-Relevance of observational studies
Dr. Robert Ligthelm
Medical Director, EHM-Hoofddorp
Rotterdam, The Netherlands
目前循證治療日益被強(qiáng)調(diào)，隨機(jī)對(duì)照臨床試驗(yàn)（RCT）的指導(dǎo)意義不容忽視。Ligthelm教授指出，更接近于臨床的大規(guī)模觀察性研究也能為臨床治療提供參考。門冬胰島素30作為應(yīng)用多年的預(yù)混胰島素類似物，研究證據(jù)豐富，不論RCT還是觀察性研究都顯示了對(duì)HbA1c、FPG和PPG的良好控制，而且低血糖發(fā)生率低。大規(guī)模觀察性研究IMPROVE進(jìn)一步顯示，門冬胰島素30可改善患者生活質(zhì)量。
In the past there has been an unprecedented development in clinical research methods to address the needs of diverse clinical specialties and practices. As such, trial designs and statistical methodology have become sophisticated. One design that has proven to be imperative to evaluating the efficacy and tolerability of a new drug is the randomised clinical trial (RCT). The RCT study design, like any, can bring drawbacks and challenges, leaving gaps in the evidence-base that observational studies are ideally suited to fill. Ongoing improvements in study methods and advances in statistical analysis have brought observational studies to the forefront of research design thereby remaining as an important source of evidence. Today Dr Ligthelm will provide an overview of the relevance of observational studies in clinical research and how trials with NovoMix? 30 show comparable results versus those conducted as RCT.
Robert Ligthelm教授：從RCT到臨床實(shí)踐
?
?
?查看分頁(yè)P(yáng)PT： http://www.sipuyun.cn/2009asia_summit/article/i9916.html
編輯: xiaoyan
以下網(wǎng)友留言只代表網(wǎng)友個(gè)人觀點(diǎn)，不代表網(wǎng)站觀點(diǎn)
